Weekly formulation of fluoxetine for newly treated patients with depression

Clinical Drug Investigation

Volumn 22, Issue 6, 2002, Pages 403-405

  Kabinoff, Gary S ^a   Plewes, John M ^b   Wilson, Michael G ^c  

^a Martin Memorial Medical Center   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c BUTLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG FORMULATION; ENTERIC COATED TABLET; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; SYMPTOM;

EID: 0036282165     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222060-00009     Document Type: Article

References (9)

1. Long-term treatment of depression
2. Adequacy and duration of antidepressant treatment in primary care
3. The national depressive and manic-depressive association consensus statement on the undertreatment of depression
4. Plasma-level response relationships with fluoxetine and zimelidine
5. Selective serotonin reuptake inhibitors: Pharmacologic profiles and potential therapeutic distinctions
6. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder
7. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder
8. Cohort experience in 39 psychiatric outpatients with high doses of an enteric-coated weekly formulation of fluoxetine
9. Once-weekly fluoxetine